Live
Hetero, the drug firm has said that it has got approval from the regulator DCGI for its generic Sofosbuvir and Velpatasvir combination tablets that are used in the treatment of chronic hepatitis C.
Hetero has said in a statement that the company “has received the approval for the generic version of ‘Sofosbuvir+Velpatasvir’ combination from the Drugs Controller General of India (DCGI).”
It added that the product will be marketed and distributed under the brand name ‘Velasof’ in India through Hetero Healthcare Ltd.
